CN113262312B - 靶向肾脏的近红外荧光探针及其制备方法和应用 - Google Patents
靶向肾脏的近红外荧光探针及其制备方法和应用 Download PDFInfo
- Publication number
- CN113262312B CN113262312B CN202110408215.7A CN202110408215A CN113262312B CN 113262312 B CN113262312 B CN 113262312B CN 202110408215 A CN202110408215 A CN 202110408215A CN 113262312 B CN113262312 B CN 113262312B
- Authority
- CN
- China
- Prior art keywords
- kidney
- polypeptide
- probe
- targeting
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000007850 fluorescent dye Substances 0.000 title claims description 22
- 210000003734 kidney Anatomy 0.000 claims abstract description 60
- 230000008685 targeting Effects 0.000 claims abstract description 36
- 239000000523 sample Substances 0.000 claims abstract description 33
- 229920001184 polypeptide Polymers 0.000 claims abstract description 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 28
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000000799 fluorescence microscopy Methods 0.000 claims abstract description 11
- 239000012216 imaging agent Substances 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- 239000002105 nanoparticle Substances 0.000 claims description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- 239000000975 dye Substances 0.000 claims description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 10
- 150000003384 small molecules Chemical class 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 238000005859 coupling reaction Methods 0.000 claims description 8
- 239000008367 deionised water Substances 0.000 claims description 8
- 229910021641 deionized water Inorganic materials 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 7
- 239000010931 gold Substances 0.000 claims description 7
- 229910052737 gold Inorganic materials 0.000 claims description 7
- 239000002096 quantum dot Substances 0.000 claims description 7
- 238000002390 rotary evaporation Methods 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 6
- 241000699670 Mus sp. Species 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000002504 physiological saline solution Substances 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000011503 in vivo imaging Methods 0.000 claims description 3
- 229910052761 rare earth metal Inorganic materials 0.000 claims description 3
- 150000002910 rare earth metals Chemical class 0.000 claims description 3
- 239000012099 Alexa Fluor family Substances 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 239000012295 chemical reaction liquid Substances 0.000 claims description 2
- 238000004440 column chromatography Methods 0.000 claims description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 2
- 238000012632 fluorescent imaging Methods 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 abstract description 6
- 239000007924 injection Substances 0.000 abstract description 6
- 230000014759 maintenance of location Effects 0.000 abstract description 5
- 208000017169 kidney disease Diseases 0.000 abstract description 4
- 206010061481 Renal injury Diseases 0.000 abstract description 3
- -1 amino, carboxyl Chemical group 0.000 abstract description 3
- 208000037806 kidney injury Diseases 0.000 abstract description 3
- 239000012620 biological material Substances 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 238000003384 imaging method Methods 0.000 description 10
- 239000000843 powder Substances 0.000 description 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- QUMKPKWYDVMGNT-NUMRIWBASA-N Asn-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O QUMKPKWYDVMGNT-NUMRIWBASA-N 0.000 description 2
- WDTAKCUOIKHCTB-NKIYYHGXSA-N Glu-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)O)N)O WDTAKCUOIKHCTB-NKIYYHGXSA-N 0.000 description 2
- IXHKPDJKKCUKHS-GARJFASQSA-N Lys-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N IXHKPDJKKCUKHS-GARJFASQSA-N 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- CAOYHZOWXFFAIR-CIUDSAMLSA-N Ser-His-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O CAOYHZOWXFFAIR-CIUDSAMLSA-N 0.000 description 2
- BVOVIGCHYNFJBZ-JXUBOQSCSA-N Thr-Leu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O BVOVIGCHYNFJBZ-JXUBOQSCSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 108010061238 threonyl-glycine Proteins 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OTCJMMRQBVDQRK-DCAQKATOSA-N Arg-Asp-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O OTCJMMRQBVDQRK-DCAQKATOSA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- ADZGCWWDPFDHCY-ZETCQYMHSA-N Gly-His-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 ADZGCWWDPFDHCY-ZETCQYMHSA-N 0.000 description 1
- GMTXWRIDLGTVFC-IUCAKERBSA-N Gly-Lys-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMTXWRIDLGTVFC-IUCAKERBSA-N 0.000 description 1
- BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 1
- LWHUUHCERHMOAB-WDSOQIARSA-N Trp-Pro-His Chemical compound N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O LWHUUHCERHMOAB-WDSOQIARSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000012984 biological imaging Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 108010033719 glycyl-histidyl-glycine Proteins 0.000 description 1
- 108010036413 histidylglycine Proteins 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明属于生物材料技术领域，具体为一种靶向肾脏的近红外发光探针及其制备方法和应用。本发明的近红外发光探针由肾脏靶向多肽与发光材料共价连接组成；多肽氨基酸侧链的残基（包括氨基、羧基或巯基）与荧光分子形成化学键合；多肽用于增强荧光分子的水溶性以及靶向肾脏中的肾小管结构；荧光分子用于荧光成像。本发明的肾脏靶向探针对肾脏靶向特异性高，70%以上注射剂量的探针在肾脏富集，所述肾脏靶向探针在肾脏中靶向停留时间大于48 h，可作为特异性肾脏靶向荧光成像剂，用于可用于对早期肾损伤状态进行诊断以及肾疾病治疗药物的靶向递送。
Description
技术领域
本发明属于生物材料技术领域，具体涉及一种基于靶向肾脏的荧光探针及其制备方法和应用。
背景技术
肾脏疾病在早期通常是没有临床症状的，但随着肾脏疾病的发展最终可能导致严重的肾功能衰竭。全世界近10%的成年人患有早期无症状的肾脏疾病，这些疾病每年导致约200万人死于后期的肾衰竭。目前临床对于肾脏疾病的诊断方法依赖于测定血尿素氮(BUN)和血肌酐(sCr)，然而，这些标志物往往在早期肾损伤时没有明显变化，在约50%的肾小球滤过率(GFR)丧失之前，这些临床检查标志物仍保持在正常范围内，因此不能用于早期肾损伤检测。非侵入性活体成像技术，如单光子发射计算机断层扫描(SPECT)，磁共振成像(MRI)，正电子发射断层扫描/计算机断层扫描(PET/CT)能被用于评估不同阶段的肾脏功能障碍，然而这些战略受到其高成本、辐射风险和低可及性的限制。
基于荧光的成像技术具有快速反馈、非电离辐射、高时空分辨率和灵敏度高等优点，可以直接显示生物体内的动态变化，目前已广泛应用于生物成像和生物传感领域。尤其是利用近红外第二窗口成像穿透更深，能降低生物组织的自身荧光，提高信噪比，更适合在活体深层组织成像。基于肾脏对小颗粒的快速滤过与清除能力，一些直径低于肾脏滤过阈值(5.5 nm)的超小荧光纳米材料包括金纳米颗粒(GNP)、量子点(QD)、康奈尔点和分子探针等可以用来对肾功能进行荧光成像。但是荧光探针的靶向成像通常需要分子具有特定的结构或特性，例如，肾探针分子需要能够通过肾脏清除代谢。而基于肾清除通路的肾脏荧光成像，探针在肾脏内停留时间短，且荧光信号会随排尿而波动，造成成像诊断或靶向药物递送的不稳定性。因此开发能够长时间靶向肾脏的探针从而进行肾脏荧光成像仍是一项挑战。在本发明中，我们设计了一种能用于长期靶向肾脏的荧光探针，通过将有机小分子或纳米颗粒与高极性的多肽偶联，从而实现在肾脏中高效长期的积累。
发明内容
本发明的目的在于提供一种制备工艺简单、水溶性好、生物相容性好，多肽肾脏靶向效率高且靶向停留时间长的荧光探针及其制备方法及其应用。
本发明提供的多肽靶向肾脏的荧光探针，由肾脏靶向多肽与发光材料共价连接组成；多肽氨基酸侧链的残基（包括氨基、羧基或巯基）与荧光分子形成化学键合；其中，多肽用于增强荧光分子的水溶性以及靶向肾脏中的肾小管结构；荧光分子用于荧光成像。本发明通过筛选多肽序列，选取不同荧光分子调控探针在肾脏中的靶向时间，最终得到可以高效长期靶向于肾脏的荧光探针。
本发明中，所述肾靶向多肽（记为KTPs）序列为：
SHSNTQTLAKAPEHTGC(SEQ. ID.NO 1) （记为KTP1）；
GHGNTQTLAKAPEHTGC(SEQ. ID.NO 2)（记为KTP2）；
SHSSTARDLWPHGKEGC(SEQ. ID.NO 3)（记为KTP3）；
优选KTP1。
本发明中，所述荧光分子包括有机小分子染料与无机纳米颗粒，所述有机小分子选自：cy3、cy5、FITC、AlexaFluor、DyLight、ICG、CX2、FD1080、LZ105；无机纳米颗粒选自金纳米颗粒GNP、量子点QD、康奈尔点CD、稀土纳米颗粒RENP。
本发明所提出的靶向肾脏的荧光探针制备方法，包括多肽-有机小分子荧光探针的制备和多肽-无机纳米荧光探针的制备两个部分；其中：
（1）多肽-有机小分子荧光探针制备的具体步骤为：
将有机小分子染料溶于有机溶剂中，使用EDC/NHS进行活化，随后将反应液旋转蒸发干燥，再用柱色谱分离，得到活化后的小分子染料；将上述小分子染料溶于溶剂中，使用三乙胺调节溶液pH值，并加入多肽进行偶联反应，得最终产物；其中，溶剂选自氯仿、二氯甲烷、甲醇、乙酸乙酯、二甲基甲酰胺，二甲基亚砜、去离子水中的一种或几种；小分子染料与EDC/NHS、多肽的反应摩尔比为(1-10) : (1-30)/(1-50) : 1；活化时间为5-40 h，活化温度为20-65摄氏度；调节溶液pH值范围为7-12；与多肽偶联时间为3-48 h，偶联反应温度为20-95摄氏度。
上述反应中，优选的技术方案为，有机染料分子的浓度为100 µM-5 mM，溶剂为二氯甲烷或甲醇，EDC/NHS的浓度为300 µM-5 mM/500 µM-10 mM，活化温度为20-40摄氏度，活化时间为12-24 h，所述的多肽的摩尔浓度为1 µM-2 mM，与多肽偶连反应时间为6-12 h，反应pH值为7-9。
本发明中，所得多肽-有机小分子荧光探针产物生成后，使用真空旋转干燥除去溶剂，并用甲醇或二氯甲烷重新分散干燥产物，弃上清溶液得沉淀产物，用甲醇或二氯甲烷重复清洗所得沉淀并干燥，得最终肾脏靶向探针。
（2）多肽-无机纳米荧光探针制备的具体步骤为：
将无机纳米颗粒溶于溶剂中，加入多肽进行配位反应，即得最终产物；其中，所述溶剂选自氯仿、二氯甲烷、甲醇、乙醇、二甲基甲酰胺，二甲基亚砜、去离子水中的一种或几种；无机纳米颗粒与多肽的反应质量浓度比为(1-10) : 1；反应时间为3-48 h，反应温度为20-95摄氏度。
上述反应中，为了保证肾脏靶向探针的合成，优选的技术方案为，所述的无机纳米材料的质量浓度为5-20 mg/mL，溶剂为去离子水或二甲基亚砜，所述多肽的质量浓度为2-10 mg/mL。反应时间为12-18 h。
本发明中，所得多肽-无机纳米荧光探针产物生成后，使用葡聚糖凝胶色谱柱分离并干燥，得最终肾脏靶向纳米探针（固体粉末）。
本发明中，所述肾脏靶向探针，对肾脏靶向特异性高，70 %以上注射剂量的探针在肾脏富集，所述肾脏靶向探针在肾脏中靶向停留时间大于48 h，可以用于制备特异性肾脏靶向荧光成像剂。
本发明中，所述肾脏靶向荧光成像剂，是将肾靶向探针（固体粉末）溶于去离子水或生理盐水中，浓度为0.5-5 mg/mL。
本发明中，所述肾脏靶向荧光成像剂，通过小鼠静脉注射进行肾脏活体成像；具体操作步骤为：使用胰岛素针取100-300 µL，通过尾静脉注射到小鼠体内；在荧光成像装置下，5-10 min后可观察到荧光探针在小鼠肾脏部位聚集，在肾脏中靶向停留时间超过48 h。
附图说明
图1为肾脏靶向探针ICG-KTP1的吸收和发射光谱图。
图2为金纳米颗粒GNP、量子点QD及稀土纳米颗粒RENP的透射电镜图。
图3为肾脏靶向探针GNP-KTP1注射后不同时间点在小鼠体内的生物分布。
图4肾脏靶向探针ICG-KYP1注射10 min后对小鼠肾脏成像图。
图5肾脏靶向探针ICG-KYP1注射48 h后对小鼠肾脏成像图。
图6为肾脏靶向探针GNP-KYP1注射48 h后对小鼠肾脏成像图。
具体实施方式
实施例1
称取ICG-COOH 20 mg置于圆底烧瓶，加入6 mL二氯甲烷溶解，随后加入15 mg EDC和15 mg NHS，上述反应液置于室温中避光搅拌24 h。随后使用真空旋转蒸发干燥出去反应溶剂，得活化后的ICG混合物。上述混合物使用硅胶柱色谱分离，得活化后的ICG纯产物。称取活化后的上述产物3 mg溶解于3 mL二甲基甲酰胺中，加入10 mg三乙胺调节溶液pH值为8-9，随后加入7 mg KTP1，上述反应避光置于室温搅拌12 h，得ICG-KTP1肾脏靶向探针混合物。使用真空旋转蒸发干燥去除溶剂二甲基甲酰胺，所得固体粉末用二氯甲烷重新分散，得悬浊液，弃上清取沉淀物继续用二氯甲烷清洗3次，干燥后的肾脏靶向探针ICG-KTP1产物粉末。
实施例2
称取FD1080 10 mg置于圆底烧瓶，加入4 mL二氯甲烷溶解，随后加入5 mg EDC和5mg NHS，上述反应液置于室温中避光搅拌12 h。随后使用真空旋转蒸发干燥出去反应溶剂，得活化后的FD1080混合物。上述混合物使用硅胶柱色谱分离，得活化后的FD1080纯产物。称取活化后的上述产物2 mg溶解于2 mL甲醇中，加入10 mg三乙胺调节溶液pH值为8-9，随后加入5 mg KTP2，上述反应避光置于室温搅拌12 h，得FD1080-KTP2肾脏靶向探针混合物。使用真空旋转蒸发干燥去除溶剂甲醇，所得固体粉末用乙酸乙酯重新分散，得悬浊液，弃上清取沉淀物继续用乙酸乙酯清洗3次，干燥后的肾脏靶向探针FD1080-KTP2产物粉末。
实施例3
称取金纳米颗粒GNP (粒径2.5 nm，3 mg) 置于玻璃瓶中，加入5mL去离子水溶解，随后加入KTP1多肽5 mg，将上述反应瓶置于45摄氏度水浴锅中，搅拌反应18 h，得肾脏靶向多肽偶联的金纳米颗粒。将上述产物置于旋转蒸发干燥器中除去水，得GNP-KTP1荧光探针粉末。使用葡聚糖凝胶G25色谱柱对上述产物进行分离，得纯化后的肾脏靶向探针GNP-KTP1。
应用例
1、使用肾脏靶向探针ICG-KTP1对小鼠肾脏进行近红外二区成像。具体步骤如下：
取实施例1中所得ICG-KTP1探针1 mg溶解于1 mL生理盐水中，通过静脉注射200 μL上述溶液于麻醉小鼠体内，用808 nm外置激光器照射小鼠背部，激光器功率密度为120mW/cm2，1200 nm长通滤光片下可进行小鼠肾脏成像(参见图4-5)；
2、使用肾脏靶向纳米探针GNP-KTP1对小鼠肾脏进行成像。具体步骤如下：
取实施例3中所得GNP-KTP1探针1 mg溶解于1 mL生理盐水中，通过静脉注射200 μL上述溶液于麻醉小鼠体内，用655 nm外置激光器照射小鼠背部，激光器功率密度为200mW/cm2，850 nm长通滤光片下可进行小鼠肾脏成像(参见图6)。
序列表
<110> 复旦大学
<120> 靶向肾脏的近红外荧光探针及其制备方法和应用
<130> 001
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 17
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Ser His Ser Asn Thr Gln Thr Leu Ala Lys Ala Pro Glu His Thr Gly
1 5 10 15
Cys
<210> 2
<211> 17
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Gly His Gly Asn Thr Gln Thr Leu Ala Lys Ala Pro Glu His Thr Gly
1 5 10 15
Cys
<210> 3
<211> 17
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 3
Ser His Ser Ser Thr Ala Arg Asp Leu Trp Pro His Gly Lys Glu Gly
1 5 10 15
Cys
Claims (3)
1.一种近红外发光探针在制备特异性肾脏靶向荧光成像剂中的应用，该探针由肾脏靶向多肽与发光材料共价连接组成，其中多肽氨基酸侧链的残基与荧光分子形成化学键合；所述肾脏靶向多肽序列为：SHSNTQTLAKAPEHTGC；其中，所述荧光分子包括有机小分子染料与无机纳米颗粒，所述有机小分子选自：cy3、cy5、FITC、AlexaFluor、DyLight、ICG、CX2、FD1080、LZ105；所述无机纳米颗粒选自金纳米颗粒GNP、量子点QD、康奈尔点CD、稀土纳米颗粒RENP；
所述近红外发光探针的制备方法包括多肽-有机小分子荧光探针的制备和多肽-无机纳米荧光探针的制备两个部分；其特征在于：
（1）多肽-有机小分子荧光探针制备的具体步骤如下：
将有机小分子染料溶于有机溶剂中，使用EDC/NHS进行活化，随后将反应液旋转蒸发干燥，再用柱色谱分离，得到活化后的有机小分子染料；
将上述活化后的有机小分子染料溶于溶剂中，使用三乙胺调节溶液pH值，并加入多肽，进行偶联反应，即得最终产物；其中，所述溶剂选自氯仿、二氯甲烷、甲醇、乙酸乙酯、二甲基甲酰胺，二甲基亚砜、去离子水中的一种或几种；所述有机小分子染料与EDC/NHS、多肽的反应摩尔比为(1-10) : (1-30)/(1-50) : 1；活化时间为5-40 h，活化温度为20-65摄氏度；调节溶液pH值范围为7-12；与多肽偶联时间为3-48 h，偶联反应温度为20-95摄氏度；
（2）多肽-无机纳米荧光探针制备的具体步骤为：
将无机纳米颗粒溶于溶剂中，加入多肽进行配位反应，即得最终产物；其中，所述溶剂选自氯仿、二氯甲烷、甲醇、乙醇、二甲基甲酰胺，二甲基亚砜、去离子水中的一种或几种；无机纳米颗粒与多肽的反应质量浓度比为(1-10) : 1；反应时间为3-48 h，反应温度为20-95摄氏度。
2. 根据权利要求1所述的应用，是将肾脏靶向荧光成像剂溶于去离子水或生理盐水中，浓度为0.5-5 mg/mL。
3.根据权利要求1所述的应用，所述肾脏靶向荧光成像剂，通过小鼠静脉注射进行肾脏活体成像。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110408215.7A CN113262312B (zh) | 2021-04-16 | 2021-04-16 | 靶向肾脏的近红外荧光探针及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110408215.7A CN113262312B (zh) | 2021-04-16 | 2021-04-16 | 靶向肾脏的近红外荧光探针及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113262312A CN113262312A (zh) | 2021-08-17 |
| CN113262312B true CN113262312B (zh) | 2022-05-20 |
Family
ID=77228781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110408215.7A Active CN113262312B (zh) | 2021-04-16 | 2021-04-16 | 靶向肾脏的近红外荧光探针及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113262312B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115569201B (zh) * | 2022-09-28 | 2024-05-28 | 四川大学华西医院 | 一种导航干细胞靶向肾脏病灶组织的多酚纳米颗粒及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107249647A (zh) * | 2014-12-15 | 2017-10-13 | 纪念斯隆-凯特琳癌症中心 | 具有增强的神经结合选择性的环状肽、与所述环状肽结合的纳米颗粒和此二者用于实时体内神经组织成像的用途 |
| CN110665016A (zh) * | 2019-10-25 | 2020-01-10 | 国家纳米科学中心 | 一种成像探针及其制备方法和应用 |
| CN110831634A (zh) * | 2017-03-08 | 2020-02-21 | 密歇根大学董事会 | 磷脂酰肌醇蛋白聚糖-3肽试剂和方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010121023A2 (en) * | 2009-04-15 | 2010-10-21 | The Regents Of The University Of California | Peptides and aptamers for targeting of neuron or nerves |
| US9931412B2 (en) * | 2013-02-08 | 2018-04-03 | The Regents Of The University Of Michigan | Targeted theranostics |
| EP3638290A4 (en) * | 2017-06-15 | 2021-04-07 | Blaze Bioscience, Inc. | KIDNEY HOMING PEPTIDE CONJUGATES AND METHOD OF USING THEREOF |
-
2021
- 2021-04-16 CN CN202110408215.7A patent/CN113262312B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107249647A (zh) * | 2014-12-15 | 2017-10-13 | 纪念斯隆-凯特琳癌症中心 | 具有增强的神经结合选择性的环状肽、与所述环状肽结合的纳米颗粒和此二者用于实时体内神经组织成像的用途 |
| CN110831634A (zh) * | 2017-03-08 | 2020-02-21 | 密歇根大学董事会 | 磷脂酰肌醇蛋白聚糖-3肽试剂和方法 |
| CN110665016A (zh) * | 2019-10-25 | 2020-01-10 | 国家纳米科学中心 | 一种成像探针及其制备方法和应用 |
Non-Patent Citations (3)
| Title |
|---|
| A Promising NIR-II Fluorescent Sensor for Peptide-Mediated Long-Term Monitoring of Kidney Dysfunction;Ying Chen et al;《Angew. Chem. Int. Ed.》;20210420;第60卷;第15809-15815页 * |
| Noninvasive Staging of Kidney Dysfunction Enabled by Renal-Clearable Luminescent Gold Nanoparticles;Mengxiao Yu et al;《Angew. Chem. Int. Ed.》;20160122;第55卷;第2787-2791页 * |
| 近红外荧光成像技术在肾脏手术中的应用进展;张瑞 等;《现代泌尿外科杂志》;20190430;第24卷(第4期);第316-319页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113262312A (zh) | 2021-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hu et al. | Gadolinium-chelated conjugated polymer-based nanotheranostics for photoacoustic/magnetic resonance/NIR-II fluorescence imaging-guided cancer photothermal therapy | |
| Qi et al. | Aggregation‐induced emission luminogens: union is strength, gathering illuminates healthcare | |
| Chen et al. | Fabrication of fluorescent nanoparticles based on AIE luminogens (AIE dots) and their applications in bioimaging | |
| EP1973575B1 (en) | Biocompatible fluorescent metal oxide nanoparticles | |
| Shen et al. | Recent development of small-molecule organic fluorophores for multifunctional bioimaging in the second near-infrared window | |
| Yen et al. | Design and synthesis of polymer-functionalized NIR fluorescent dyes–magnetic nanoparticles for bioimaging | |
| CN106390143B (zh) | 肿瘤靶向核磁共振/荧光双模态成像造影剂及其制备和应用 | |
| JP4560209B2 (ja) | 診断および治療に有用な非共有結合的バイオコンジュゲート | |
| CN102861344B (zh) | 叶酸修饰聚乙二醇化树状大分子包裹的金纳米颗粒的制备 | |
| Liu et al. | Croconaine-based nanoparticles enable efficient optoacoustic imaging of murine brain tumors | |
| KR101183732B1 (ko) | 광역학 진단 또는 치료를 위한 아세틸화된 다당류 및 광감작제가 결합된 결합체 및 이의 제조방법 | |
| Zhang et al. | Applications of CBT-Cys click reaction: Past, present, and future | |
| Thangudu et al. | Recent advances in near infrared light responsive multi-functional nanostructures for phototheranostic applications | |
| KR100825939B1 (ko) | 근적외선 형광체가 결합된 양친성 고분자의 나노 입자를포함하는 암 진단용 조영제 | |
| CN113262312B (zh) | 靶向肾脏的近红外荧光探针及其制备方法和应用 | |
| Liu et al. | Polymeric nanosystems for near-infrared multispectral photoacoustic imaging: Synthesis, characterization and in vivo evaluation | |
| WO2005000218A2 (en) | Macrocyclic cyanine and indocyanine bioconjugates provide improved biomedical applications | |
| CN104225630B (zh) | 适用于mri/pa及其他成像的多模式自组装纳米探针 | |
| Jiang et al. | Design and application of organic contrast agents for molecular imaging in the second near infrared (NIR-II) window | |
| Qiu et al. | Liver injury long-term monitoring and fluorescent image-guided tumor surgery using self-assembly amphiphilic donor-acceptor NIR-II dyes | |
| CN104117073B (zh) | 一种双模式成像纳米胶束及其制备方法和用途 | |
| An et al. | A reticuloendothelial system-stealthy dye–albumin nanocomplex as a highly biocompatible and highly luminescent nanoprobe for targeted in vivo tumor imaging | |
| Zhu et al. | Self-Assembly of Precisely Fluorinated Albumin for Dual Imaging-Guided Synergistic Chemo–Photothermal–Photodynamic Cancer Therapy | |
| CN107303388B (zh) | 一种基于近红外染料-透明质酸复合物的诊断治疗制剂 | |
| Gowtham et al. | Nano-fluorophores as enhanced diagnostic tools to improve cellular imaging. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |